[F]FDG PET/CT for predicting neoadjuvant PD-L1 blockade monotherapy treatment response in patients with locally advanced esophageal squamous cell carcinoma: a preliminary study.

Purpose: To investigate the predictive value of 2-[18F]-fluoro-2-deoxy-D-glucose ([F]FDG) PET/CT for evaluating primary tumor (PT) and lymph node (LN) responses after neoadjuvant programmed death-ligand 1 (PD-L1) blockade monotherapy in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC).

Methods: In the single-arm phase 1b NATION-1907 trial (NCT04215471), 23 patients with LA-ESCC received two cycles of neoadjuvant PD-L1 blockade Adebrelimab followed by surgery. Among these, 18 patients underwent [F]FDG PET/CT scans both before immunotherapy and prior to surgery.

Clinical Explorations of [Ga] Ga-FAPI-04 and [F] FDG Dual-Tracer Total-body PET/CT and PET/MR Imaging.

Fibroblast activation protein inhibitor (FAPI) and [F]fluorodeoxyglucose ([F]FDG) provide complementary biological information, and FAPI/FDG dual-tracer imaging clinical application is increasing recently. However, optimal protocols for FAPI/FDG dual-tracer positron emission tomography/computed tomography (PET/CT) and PET/magnetic resonance (PET/MR) imaging are still under investigation. Due to its high sensitivity, total-body PET/CT allows for imaging with minimal tracer activity and supports the creation of new dual-tracer PET/CT imaging protocols.

The earliest optimal timing for total-body Ga-fibroblast activation protein inhibitor-04 PET scans: an evidence-based single-centre study.

Objectives: To investigate the earliest optimal timing for positron emission tomography (PET) scans after Ga-fibroblast activation protein inhibitor-04 ([Ga]Ga-FAPI-04) injection.

Methods: This prospective study enrolled patients who underwent 60-min dynamic Ga-FAPI-04 total-body PET/CT scans; the images were reconstructed at 10-min intervals (G0-10, G10-20, G20-30, G30-40, G40-50, and G50-60), and the [Ga]Ga-FAPI-04 uptake patterns were evaluated. The standardised uptake value (SUV), liver signal-to-noise ratio (SNR), and lesion-to-background ratios (LBRs) for different time windows were calculated to evaluate image quality and lesion detectability.

Recovery of phosphate as struvite from low-temperature combustion sewage sludge ash (LTCA) by cation exchange.

As a phosphorus-rich material, low-temperature combustion sewage sludge ash (LTCA) contains over 9 wt% content of phosphorus (P) and a large proportion of impurities, especially the content of Fe arrives at 14.59 wt%. To fully utilize LTCA as a fertilizer, this study investigated a procedure for P recovery from LTCA via struvite crystallization with fewer impurities.

Improved utilization of phosphorous from sewage sludge (as Fertilizer) after treatment by Low-Temperature combustion.

The utilization of phosphorus from sewage sludge is an important method used to solve the shortage of phosphorus resources in the world. However, high levels of toxic compounds and low phosphorus bioavailability in sewage sludge are the main factors limiting its direct agricultural use. This paper proposes a low-temperature combustion method that can enrich the phosphorus in sludge ash.

Silencing Artemis Enhances Colorectal Cancer Cell Sensitivity to DNA-Damaging Agents.

Artemis is a key protein of NHEJ (nonhomologous end joining), which is the major pathway for the repair of IR-induced DSBs in mammalian cells. However, the expression of Artemis in tumors and the influence of silencing Artemis on tumor sensitivity to radiation have not been investigated fully. In this study, we investigated how the expression levels of Artemis may affect the treatment outcome of radiotherapy and chemotherapy in colorectal cancer cells.

[Stable isotope labeling and parallel reaction monitoring-based proteomic quantification for biomarker screening and validation of hepatocellular carcinoma].

Liver cancer is the fifth most common cancer with extremely low five year survival rate. Early diagnosis is of great importance for cancer therapy. In this work, stable isotope labeling-based relative quantitative proteomics and parallel reaction monitoring-based target proteomics were combined for cancer biomarker screening and validation.

Nimotuzumab abrogates acquired radioresistance of KYSE-150R esophageal cancer cells by inhibiting EGFR signaling and cellular DNA repair.

Background: Acquired radioresistance of cancer is common after repeated irradiation and often leads to treatment failure. This study aimed to examine the effects of nimotuzumab on acquired radioresistance in human esophageal carcinoma cells and to investigate its underlying mechanisms.

Methods: The radioresistant human esophageal carcinoma cell line KYSE-150R was generated by using fractionated irradiation.